• Budesonide in Anti-Inflammatory Corticosteroid Research: App

  2026-07-08

  Budesonide stands out as an anti-inflammatory corticosteroid for high-fidelity airway inflammation and asthma models, thanks to its rapid pulmonary absorption and robust in vitro stability. This article translates cutting-edge permeability modeling findings and troubleshooting guidance into actionable protocols, enabling reproducible respiratory disease research with APExBIO’s high-purity Budesonide.

• Cabozantinib (XL184): Dynamic Kinase Inhibition in Tumor Mic

  2026-07-08

  Explore how Cabozantinib (XL184) redefines kinase inhibition in cancer research, with a focus on microenvironment adaptation and chronic exposure dynamics. Gain in-depth insights into phosphoproteomic remodeling and practical assay design, distinct from prior analyses.

• SP600125: Precision JNK Inhibitor for Apoptosis & Inflammati

  2026-07-07

  SP600125, a selective JNK inhibitor from APExBIO, empowers researchers to dissect cell signaling with unmatched specificity in apoptosis and inflammation research. Flexible in vitro and in vivo protocols, advanced troubleshooting insights, and new findings on stress pathway crosstalk make it the tool of choice for modern MAPK studies.

• Synthetic mRNA-Driven hiPSC Differentiation into Oligodendro

  2026-07-07

  This study demonstrates a rapid, transgene-free method for differentiating human-induced pluripotent stem cells (hiPSCs) into functional oligodendrocytes using a synthetic modified OLIG2 mRNA. The findings offer a safer, efficient alternative to viral gene delivery for cell-based therapies and disease modeling.

• Bi-Layer Wound Dressings: Tranexamic Acid and NO for Hemosta

  2026-07-06

  The reference paper presents a novel bi-layer wound dressing integrating tranexamic acid, nitric oxide donor, and propolis to address both rapid hemostasis and infection control in trauma injuries. This design demonstrates a synergistic approach, achieving immediate clot formation and significant antibacterial activity, offering a dual-action solution for traumatic wound management.

• Phosphatase Inhibitor Cocktail (2 Tubes, 100X): Technical Gu

  2026-07-06

  The Phosphatase Inhibitor Cocktail (2 Tubes, 100X) addresses the need for robust inhibition of endogenous phosphatases during sample preparation, preserving protein phosphorylation critical for accurate downstream analysis. It is intended for scientific research workflows such as immunoblotting, kinase activity assays, and mass spectrometry, and should not be used in diagnostic or clinical applications.

• OTUD3-SLC7A11 Axis Enables Sunitinib Resistance via Ferropto

  2026-07-05

  The reference study reveals how OTUD3 stabilizes the cystine/glutamate transporter SLC7A11, thereby enabling clear cell renal cell carcinoma (ccRCC) cells to evade sunitinib-induced ferroptosis. This mechanistic insight identifies the OTUD3-SLC7A11 axis as a promising therapeutic target for overcoming drug resistance in ccRCC.

• SAR131675: Precision VEGFR-3 Inhibitor Workflows for Tumor S

  2026-07-04

  SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor, empowers researchers to dissect lymphangiogenesis and tumor angiogenesis with nanomolar selectivity. This guide delivers actionable protocols, troubleshooting intelligence, and advanced applications that differentiate SAR131675 in the landscape of anti-lymphangiogenic and anti-angiogenic research.

• A-769662: Redefining AMPK Activation and Autophagy Control

  2026-07-03

  Explore how A-769662, a potent AMPK activator, is reshaping the landscape of energy metabolism and autophagy research. This in-depth analysis integrates new mechanistic insights and highlights practical implications for metabolic and cell cycle studies.

• Carfilzomib (PR-171): Reliable Proteasome Inhibition in Canc

  2026-07-03

  This evidence-driven guide addresses common laboratory challenges in cell viability, proliferation, and cytotoxicity assays by leveraging Carfilzomib (PR-171) (SKU A1933). Integrating scenario-based Q&A, recent mechanistic findings, and protocol best practices, it empowers biomedical researchers to achieve reproducible, high-sensitivity results in proteasome inhibition workflows.

• L-Alanyl-L-Glutamine: Technical Guidance for Research Workfl

  2026-07-02

  L-Alanyl-L-Glutamine (SKU B8228) offers a highly stable, water-soluble dipeptide solution for supporting intestinal mucosa protection, particularly when glutamine instability is a concern. It is ideal for workflows requiring reliable antioxidant system support and intestinal barrier function enhancement, but should not be used in DMSO- or ethanol-based assays due to insolubility.

• SAR131675: Advancing VEGFR-3 Inhibition in Fibrosis Research

  2026-07-02

  This article explores the mechanistic and translational impact of SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor, in the context of fibrosis and tumor biology. Integrating recent findings on the VEGFC–macrophage axis in NASH and benchmarking SAR131675’s application workflows, we provide actionable guidance for translational researchers seeking robust, pathway-specific insights into lymphangiogenesis, angiogenesis, and immune modulation.

• Dovitinib (TKI-258): Applied RTK Inhibition in Cancer Models

  2026-07-01

  Dovitinib (TKI-258) sets the benchmark for multitargeted RTK inhibition in translational cancer research, enabling robust apoptosis induction and pathway dissection in hypoxia-adapted tumor models. This guide details practical workflows, troubleshooting insights, and protocol refinements to unlock the full potential of Dovitinib in both in vitro and in vivo oncology studies.

• Rotavirus NSP4 Drives Necroptosis via Host RIPK Complex and

  2026-07-01

  This study elucidates how rotavirus non-structural protein 4 (NSP4) orchestrates MLKL-dependent necroptotic cell death by commandeering the host RIPK1-RIPK3 complex. Through a unique mechanism involving ER-to-cytosol calcium efflux, NSP4 enables necrosome assembly and cell death, providing new insight into viral modulation of programmed cell death pathways with relevance for calcium signaling research.

• Thiamet G: O-GlcNAcase Inhibitor Workflows & Preeclampsia In

  2026-06-30

  Thiamet G empowers precise O-GlcNAcylation control for disease models, from neurodegeneration to preeclampsia. This guide spotlights workflow enhancements, troubleshooting, and new translational directions unlocked by recent breakthroughs in trophoblast ferroptosis research.

15621 records 1/1042 page Next 12345 下5页 Last page